FDA
-
-
-
-
-
-
-
Emergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States
-
-
-
-
-
-
-
Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Emergent BioSolutions (EBS)
-
-
-
-
-
-
-
Emergent BioSolutions Underscores Continued Support of Increasing Naloxone Awareness Through Public Education Campaign on International Overdose Awareness Day
-
-
-
-
-
-
-
Emergent BioSolutions Supports Victoria's Voice Foundation’s National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies
-
-
-
-
-
-
-
Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International
-
-
-
-
-
-
-
Emergent BioSolutions (EBS) Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS
-
322,874 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

